Lengthy timelines and high costs remain major challenges in pharmaceutical R&D. As pressure grows to bring medicines to patients faster, laboratories must find smarter ways to accelerate their ...
insights from industryBernd GleixnerDivision President AutomationBruker Biopsin News Medical speaks to Bernd Gleixner, Division President Automation at Bruker Biospin, about the future of lab ...
Every stage of biopharma drug development depends on what happens in the laboratory. Consequently, any one of these stages—which include target identification, lead optimization, candidate screening, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results